Newer gene immunotherapies, such as CAR T-cell therapies, can provide life-saving treatments for patients with rare blood disorders. Associate Partner Dennis Fournogerakis describes in PM360 Magazine how manufacturers can overcome commercial challenges at launch and beyond to help treatment centers offer these cutting-edge therapies to patients who need it most.
Read Full Article